| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
2e-07 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
3e-07 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
6e-07 |
| mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-06 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
1e-06 |
| mRNA |
BRD-K34222889 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
1e-06 |
| mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
3e-06 |
| mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
4e-06 |
| mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
6e-06 |
| mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
6e-06 |